Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Esaxerenone Monotherapy or Combination Therapy in Japanese Patients with Essential Hypertension
jRCT2080223121Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of esaxerenone in essential hypertension (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Long-term safety of esaxerenone. Started Mar 2016; status: completed.
02
Drugs
esaxerenone
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080223121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223121.